MoslehiJJ.Cardiovascular toxic effects of targeted cancer therapies.N Engl J Med2016;
375: 1457–1467.
2.
TiniGSarocchiMTocciG, et al.
Arterial hypertension in cancer: the elephant in the room. Int J Cardiol2019;
281: 133–139.
3.
CameronACTouyzRMLangNN.Vascular complications of cancer chemotherapy. Can J Cardiol2016;
32: 852–862.
4.
LiuFHidruTHGaoR, et al.
Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities. J Hypertens2020;
38: 426–433.
5.
TiniGSarocchiMAmeriP, et al.
The need for cardiovascular risk factor prevention in cardio-oncology. JACC: Heart Fail2019;
7: 367–368.
6.
ManciaGFagardRNarkiewiczK, et al.
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).Eur Heart J Oxford Academic2013;
34: 2159–2219.
7.
WilliamsBManciaGSpieringW, et al.
2018 ESC/ESH guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J Oxford Academic2018;
39: 3021–3104.
8.
CatapanoALGrahamIDe BackerG, et al.
2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J2016;
37: 2999–3058.
9.
TouyzRMHerrmannSMSHerrmannJ.Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. J Am Soc Hypertens2018;
12: 409–425.
10.
D’AscenziFAnselmiFFiorentiniC, et al. The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. Eur J Prev Cardiol. Epub ahead of print 2019. DOI: 10.1177/2047487319874900.
